secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001714899-26-000036
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.03, 1.01, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Therapeutics receives $200M from Royalty Pharma after FDA approval of tividenofusp alfa
--------------------------------------------------------------------------------

- Received $200.0M gross proceeds from Royalty Pharma under synthetic royalty funding agreement.
- Closing followed FDA accelerated approval of tividenofusp alfa on March 24, 2026.
- Synthetic royalty agreement was previously announced on December 4, 2025.
- Proceeds provide non-dilutive capital for further development and commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489926000036/0001714899-26-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489926000036/dnli-20260327.htm
  HTML page:      https://secwatch.observer/filing/0001714899-26-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer